Venous thromboembolism in patients with COVID-19. A prevalent and a preventable complication of the pandemic

Razi, Murtuza; Gu, Jianping; He, Xu; Kong, Jie; Ahmed, Mohammed Jameeluddin

doi:10.1016/j.jimed.2021.02.006

Cited by 4 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using thromboprophylaxis is strongly recommended for moderate-severe COVID-patients [26]. Co-morbid diseases including congestive heart failure, cancer, and diabetes make the risk of thrombosis even higher [27].…”

Section: Special Therapeutic and Nursing Considerations Of The Elderl...mentioning

confidence: 99%

COVID-19 and the elderly

Gadó

Kovács

Domján

et al. 2022

PhysInt

View full text Add to dashboard Cite

COVID-19 has become a great burden of the world in respect of health care, social, and economical reason. Several million people died worldwide so far and more and more mutants are generated and spread. Older people with co-morbidities and frailty syndrome have a significantly higher risk to get the infection and also higher the risk of a more serious disease process. Mortality of COVID-19 is also higher in case of geriatric patients. In this review we attempted to summarize the factors of the higher susceptibility for more serious disease, what actions need to be taken for defending older patients and also special aspects of clinical presentation including ophthalmic symptoms.

show abstract

Section: Special Therapeutic and Nursing Considerations Of The Elderl...mentioning

confidence: 99%

COVID-19 and the elderly

Gadó

Kovács

Domján

et al. 2022

PhysInt

View full text Add to dashboard Cite

show abstract

“…Our longitudinal observational study clearly described the CT imaging dynamics of Delta variant-induced pneumonia by innovatively combining AI with radiologists to identify and measure lesions, and highlighted the effects of vitamin D status on lesion dynamics and simultaneous laboratory results, which could provide references for the clinical management of Omicron variant-induced pneumonia. Some studies have reported that older age, comorbidities, coagulation dysfunction, and unvaccinated status may increase the risk of COVID-19-related acute respiratory distress syndrome (ARDS) and pneumonia (14,(20)(21)(22). Our multivariate binary logistic regression analysis obtained three independent predictors of age, fibrinogen, and SARS-CoV-2 IgG titer.…”

Section: Discussionmentioning

confidence: 72%

“…Till April 1, 2022, a total of 161 discharged adult patients infected with the Delta variant were included in this study, of which 101 (63%) were male and 46 (29%) presented with pneumonia. The median (IQR) age and baseline 25-hydroxyvitamin D concentration were 37 (28-47) years and 21 (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27) ng/ml, respectively. There were significant differences in age (34 vs. 43 years; p < 0.001), SARS-CoV-2 IgM titer (0.3 vs. 0.1 AU/ml; p = 0.002), SARS-CoV-2 IgG seropositive (84 vs. 44%; p < 0.001), and titer (82.8 vs. 3.3 AU/ml; p < 0.001), lymphocyte (1.36 vs. 0.87 × 10^9/L; p = 0.002) and platelet count (224 vs. 200 × 10^9/L; p = 0.04), fibrinogen (2.9 vs. 3.3 g/L; p < 0.001), and aspartate aminotransferase (27 vs.…”

Section: Demographic and Clinical Characteristics And Baseline Labora...mentioning

confidence: 99%

Effect of vitamin D status on adult COVID-19 pneumonia induced by Delta variant: A longitudinal, real-world cohort study

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe effect of vitamin D status on adult COVID-19 pneumonia induced by Delta variant remains to be further explored.MethodsA longitudinal, real-world cohort study was performed. Artificial intelligence (AI) was used to identify and measure pneumonia lesions. All cases with pneumonia were divided into the vitamin D deficiency (VDD) and control groups according to serum 25-hydroxyvitamin D concentration. Lesion dynamics were observed within six time periods after the onset of pneumonia.ResultsA total of 161 cases were included, of which 101 (63%) were male and 46 (29%) presented with pneumonia. The median age and baseline 25-hydroxyvitamin D concentrations were 37 years and 21 ng/ml, respectively. Age, fibrinogen, and SARS-CoV-2 IgG titer on admission were independent predictors for the onset of pneumonia. After the onset of pneumonia, patients in the VDD group (n = 18) had higher percentage of fever (33 vs. 7.1%; p = 0.04) than those in the control group (n = 28); the interval of pneumonia resolution was longer (28 vs. 21 days; p = 0.02); lesions progressed more rapidly (p = 0.01) within 3 to 7 days and improved more slowly (p = 0.007) within more than 28 days; notably, simultaneous interleukin-6 (18.7 vs. 14.6 pg/ml; p = 0.04) levels were higher, and cycle thresholds for N gene (22.8 vs. 31.3; p = 0.04) and ORF1ab gene (20.9 vs. 28.7; p = 0.03) were lower within 3 to 7 days.ConclusionVitamin D status may have effects on the progression and resolution, but not the onset of Delta variant-induced pneumonia in adults. Computed tomography image diagnosis system based on AI may have promising applications in the surveillance and diagnosis of novel SARS-CoV-2 variant-induced pneumonia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Antiviral drugs and experimental treatments provided to these individuals may increase the risk of thrombosis or hemorrhagic events through pharmacological associations with therapeutic anticoagulants. 6,34 The prognosis of COVID-19 may be improved by therapeutic anticoagulant administration before infection by impeding coagulation activation. In fact, compared to thromboprophylaxis alone, the administration of therapeutic anticoagulation at hospital admission resulted in the decreased incidence of VTE.…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes of Anticoagulant Therapy in COVID-19 Patients with Pre-Existing Cardiovascular Diseases: A Systematic Review

Alhawiti¹,

Alhawiti²,

Alshalan³

et al. 2023

IDR

View full text Add to dashboard Cite

The COVID-19 infection caused by SARS-CoV-2 is a healthcare crisis that has led to unparalleled disruption and has impacted healthcare services, leading to significant morbidity and mortality in the worldwide population. Insufficient data on the management of COVID-19 complications such as hypercoagulability and the controversy about the benefits of anticoagulant therapy are major challenges encountered by clinicians, especially for patients with pre-existing cardiovascular diseases (CVD), and are still debatable. Therefore, we endeavored to conduct a systematic review to assess the clinical outcomes of prior anticoagulant therapy in patients with COVID-19 having pre-existing CVD. Electronic searches of the PubMed database and EBSCO Information Services were carried out, and all relevant articles were employed. Seven articles with data from 21,989 subjects were included. Despite the promised clinical outcomes of anticoagulant therapy, the results of the current systematic review indicated insignificant improvements in the reduction of mortality rate or ICU admission among patients with COVID-19 having pre-existing CVD. Furthermore, direct oral anticoagulant (DOAC) were favored over vitamin K antagonists (VKAs) due to better action and less side effects. In conclusion, the findings are controversial as we did not statistically analyze the results. The data showed inconsistent information with no clear effect of anticoagulant use before patient hospitalization or decreasing COVID-19 severity, particularly in those with CVD. Further studies including randomized controlled trials are required to describe the best course as well as optimal dose of anticoagulant use in the treatment of patients with COVID-19, particularly those with comorbidities such as CVD.

show abstract

Venous thromboembolism in patients with COVID-19. A prevalent and a preventable complication of the pandemic

Cited by 4 publications

References 47 publications

COVID-19 and the elderly

COVID-19 and the elderly

Effect of vitamin D status on adult COVID-19 pneumonia induced by Delta variant: A longitudinal, real-world cohort study

Clinical Outcomes of Anticoagulant Therapy in COVID-19 Patients with Pre-Existing Cardiovascular Diseases: A Systematic Review

Contact Info

Product

Resources

About